NASDAQ : EDIT
Editas Medicine, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.67 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 410.06M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 410.06M |
| Enterprise Value | 213.92M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 153.58M |
| Shares Outstanding | 153.58M |
| Shares Change (YoY) | +21.72% |
| Shares Change (QoQ) | +21.88% |
| Owned by Insiders (%) | 0.20% |
| Owned by Institutions (%) | 55.05% |
| Float | 115.49M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.72 |
| Forward PS | 23.64 |
| PB Ratio | 3.89 |
| P/TBV Ratio | 3.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 4.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.19 |
| Quick Ratio | 3.13 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20.52 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -118.82% |
| Return on Assets (ROA) | -23.29% |
| Return on Invested Capital (ROIC) | -64.75% |
| Return on Capital Employed (ROCE) | -49.41% |
| Weighted Average Cost of Capital (WACC) | 15.44% |
| Revenue Per Employee | $540,287 |
| Profits Per Employee | -$849,989 |
| Employee Count | 87 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.00 |
| 52-Week Price Change | -12.17% |
| 50-Day Moving Average | 2.76 |
| 200-Day Moving Average | 2.68 |
| Relative Strength Index (RSI) | 50.80 |
| Average Volume (20 Days) | 2,509,681 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 38.19M |
| Short Previous Month | 37.11M |
| Short % of Shares Out | 24.86% |
| Short % of Float | 33.06% |
| Short Ratio (days to cover) | 11.66 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 47.01M |
| Gross Profit | -37.95M |
| Operating Income | -83.46M |
| Pretax Income | -73.95M |
| Net Income | -73.95M |
| EBITDA | -81.04M |
| EBIT | -83.46M |
| Loss Per Share | -$0.73 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 211.65M |
| Total Debt | 15.51M |
| Net Cash | 196.13M |
| Net Cash Per Share | $1.28 |
| Equity (Book Value) | 105.28M |
| Book Value Per Share | 0.69 |
| Working Capital | 149.63M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -119.86M |
| Capital Expenditures | -691,000 |
| Depreciation & Amortization | 2.43M |
| Net Borrowing | n/a |
| Free Cash Flow | -120.55M |
| FCF Per Share | -$0.78 |
Margins
| Measure | Value |
|---|
| Gross Margin | -80.74% |
| Operating Margin | -177.56% |
| Pretax Margin | -157.32% |
| Profit Margin | -157.32% |
| EBITDA Margin | -172.40% |
| EBIT Margin | -177.56% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -21.72% |
| Shareholder Yield | -21.72% |
| Earnings Yield | -27.37% |
| FCF Yield | -29.40% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $6.10 |
| Price Target Difference | 128.46% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | -27.47% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -8.85 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |